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Reverse cholesterol transport (RCT) refers to the mobilization of cholesterol on HDL particles (HDL-C) from 
extravascular tissues to plasma, ultimately for fecal excretion. Little is known about how HDL-C leaves periph-
eral tissues to reach plasma. We first used 2 models of disrupted lymphatic drainage from skin — 1 surgical and 
the other genetic — to quantitatively track RCT following injection of [3H]-cholesterol–loaded macrophages 
upstream of blocked or absent lymphatic vessels. Macrophage RCT was markedly impaired in both models, 
even at sites with a leaky vasculature. Inhibited RCT was downstream of cholesterol efflux from macrophages, 
since macrophage efflux of a fluorescent cholesterol analog (BODIPY-cholesterol) was not altered by impaired 
lymphatic drainage. We next addressed whether RCT was mediated by lymphatic vessels from the aortic wall 
by loading the aortae of donor atherosclerotic Apoe-deficient mice with [2H]6-labeled cholesterol and surgically 
transplanting these aortae into recipient Apoe-deficient mice that were treated with anti-VEGFR3 antibody to 
block lymphatic regrowth or with control antibody to allow such regrowth. [2H]-Cholesterol was retained in 
aortae of anti–VEGFR3-treated mice. Thus, the lymphatic vessel route is critical for RCT from multiple tissues, 
including the aortic wall. These results suggest that supporting lymphatic transport function may facilitate 
cholesterol clearance in therapies aimed at reversing atherosclerosis.
Introduction
Atherosclerosis is a major cause of morbidity and mortality in 
the world. At the cellular level, atherosclerotic plaques are char-
acterized by macrophages loaded with cholesterol esters. Indeed, 
ongoing recruitment of monocyte-derived macrophages into 
plaque is a key event in disease progression. Removal of macro-
phages involves a cessation of recruitment that correlates with the 
mobilization of cholesterol stored within macrophages as cho-
lesterol esters (1). Cholesterol ester–loaded macrophages are not 
inherently proinflammatory (2). Thus, it is not yet understood 
how cholesterol drives monocyte recruitment to sustain plaque 
progression. Deposition of cholesterol crystals (3) or undesirable 
immunity to cholesterol-associated apoproteins (4) are possible 
means by which inflammation can be sustained in an environ-
ment rich in macrophages and cholesterol. Regardless of our 
gaps in understanding the links between cholesterol in the artery 
wall and inflammation that drives disease progression, it seems 
clear that removal of cholesterol, which is largely stored in macro-
phages as cholesterol esters, from the aortic wall would comprise 
a step toward disease reversal, as observed in primate models of 
atherosclerosis regression (5).
Removal of cholesterol from macrophages requires hydrolysis, 
mobilization, and efflux of stored cholesterol ester from macro-
phages to lipoprotein acceptors, especially apoA-I, by virtue of 
the formation of HDL. Cholesterol solubilized by apoA-I and 
phospholipids (HDL-C) moves through the bloodstream to the 
liver for eventual fecal elimination (6), or through a nonbiliary 
pathway (7, 8). This entire transport process is called reverse 
cholesterol transport (RCT), and macrophage RCT refers specif-
ically to the removal of cholesterol from macrophage cholesterol 
ester stores (9). The fraction of cholesterol disposed of through 
macrophages is small overall compared with the amounts in the 
entire body; nonetheless, as cells that are active in tissue remod-
eling and clearance of cellular debris, macrophages may take in 
and need to dispose of more cholesterol than many other cell 
types (9, 10). Although much is known about cholesterol efflux 
from macrophages and subsequent uptake of cholesterol in the 
liver and its secretion into bile, some steps are poorly under-
stood. In particular, little is known about how HDL or apoA-I 
enters or leaves plaques, or indeed any other tissues, to return to 
the bloodstream.
The lymphatic system generally governs the transport of macro-
molecules from the extravascular space into the blood (11). 
Accordingly, human peripheral lymph contains HDL-C (12–14), 
and estimates indicate a lymph transport of more than 300 mg 
per day (15). Placed into the context of estimates of overall neutral 
and acidic sterol excretion per day per kilogram in humans (16), 
the flux through lymph could represent a substantial pathway 
for removal of cholesterol from tissues body wide. However, since 
apoA-1, which drives the formation of HDL, is thought to enter 
extravascular tissues by crossing the blood endothelium (17), it 
is unclear whether clearance of HDL-C from tissues by traversing 
vascular endothelium may also occur and diminish the need for 
lymphatic transport to remove HDL-C from tissues. Thus, we set 
out to address whether lymphatic vessels participate critically in 
RCT from peripheral tissues, including skin and the aortic wall, 
where macrophage RCT is especially relevant.
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Results
Surgical ablation of lymphatic vessels in the skin blocks RCT without 
impairing cholesterol efflux from macrophages. To determine wheth-
er lymphatic vessels have a quantitatively important role in the 
clearance of HDL, we first adapted an in vivo macrophage RCT 
assay (6, 18, 19). In this assay, RCT is measured by injection of 
[3H]-cholesterol–loaded macrophages into peripheral tissues of 
mice to track the mobilization of [3H]-cholesterol to plasma, liver, 
and feces (6, 18). In preparation for this assay, we surgically sep-
arated dermal lymphatic vessels to disrupt lymph flow from the 
tail dermis of mice without damaging the blood circulation (20). 
Intradermal injection of Evans blue dye into the tail tip, upstream 
of the separation, revealed very little dye retrieved in drain-
ing lymph nodes compared with the sham control (Figure 1A). 
This finding allowed us to set up a model to examine whether 
RCT is intact or severely disrupted after [3H]-cholesterol–loaded 
macrophages are injected into the tail upstream of the lymphatic 
separation. In control mice without lymphatic separation, the 
RCT response to [3H]-cholesterol–loaded macrophages injected 
into the tail skin was much less robust than in the lower back 
skin or the previously studied peritoneal cavity (Figure 1B and 
ref. 18), importantly revealing that different body sites support 
macrophage RCT to differing extents. As expected (18), macro-
phage RCT from the tail increased markedly in Apoa1 transgenic 
mice (Figure 1B), which bear higher levels of HDL (21). There-
fore, we utilized Apoa1 transgenic mice in ensuing macrophage 
RCT assays in the tail following lymphatic separation versus sham 
operation to improve the magnitude of our readout.
Surgical separation of tail lymphatic vessels did not alter 
plasma lipoprotein profiles (Supplemental Figure 1; supple-
mental material available online with this article; doi:10.1172/
JCI63685DS1). [3H]-Cholesterol did not appear in plasma for 
more than 8 hours after [3H]-cholesterol–loaded macrophage 
injection, but counts peaked by 24 hours (Figure 1C). [3H]-Choles-
terol levels were reduced by 50% in plasma in mice with surgically 
separated lymphatic vessels (Figure 1C). When normalized to the 
weight or volume of each compartment, there was a net reduction 
of [3H]-cholesterol in plasma, liver, and feces (Figure 1D). Surgical 
separation of lymphatic vessels in the tail reduced net RCT by 54% 
at 24 hours and by 44% at 48 hours (Figure 1D). These data sug-
gest that lymphatic vessels are important conduits for RCT.
However, it is possible that cholesterol efflux from macrophages, 
rather than egress of HDL from tissue, was reduced in the skin 
with lymphatic separation. To examine this possibility, we loaded 
macrophages ex vivo with BODIPY-cholesterol, a fluorescent ana-
log of cholesterol in which a BODIPY moiety is covalently linked 
to C24 of the aliphatic side chain (22, 23), allowing us to monitor 
cholesterol efflux from individual macrophages using flow cytom-
etry. Like native cholesterol, we found that BODIPY-cholesterol 
efflux required the expression of ABCA1/ABCG1 (Supplemental 
Figure 2). Therefore, we prepared macrophages from CD45.1+ con-
genic C57BL/6 mice, loaded them with BODIPY-cholesterol, and 
injected them into the tails of CD45.2+ WT or Apoa1 transgenic 
mice with or without lymphatic vessel separation. At 24 hours, 
we digested the tail tissue to retrieve injected cells and gated on 
CD45.1+ cells to identify the transferred macrophages. Macro-
phages injected into Apoa1 transgenic mice had reduced fluores-
cence intensity (shift to the left), indicative of increased BODIPY-
cholesterol unloading, compared with injection into WT recipient 
mice (Figure 1E). Most importantly, there was no difference in this 
shift to the left in Apoa1 transgenic mice where lymphatic vessels 
had been separated (Figure 1E), as the mean fluorescence intensity 
in WT recipients was approximately 600 in WT mice and dropped 
to 350 in both groups of Apoa1 transgenic mice. Thus, plasma lipo-
protein profiles and cholesterol efflux from macrophages were not 
significantly affected by lymphatic separation, indicating that the 
substantial reduction in RCT observed after surgically blocking 
lymphatic transport is attributable to a critical role of lymphatic 
vessels in transporting HDL-C during RCT.
Figure 1
Surgical separation of lymphatic vessels and its impact on RCT. (A) 
Image of the mouse tail following surgical separation of lymphatic 
vessels (red arrow). White boxes depict approximate location of 
tail-draining lymph nodes. These nodes (lower photomicrographs) 
were removed after Evans blue dye was injected into the tail; enlarged 
images of the 2 lymph nodes are shown from a control mouse receiving 
a sham operation (Sham) and 1 that underwent lymphatic separation 
(Surgery). Similar results were obtained in 4 other analyses (n = 5) 
using Evans blue dye to verify repeated success of the procedure. 
(B) [3H]-Cholesterol–loaded macrophages were injected into the peri-
toneum (i.p.), in skin of the tail, or the lower back of WT or Apoa1 
transgenic mice. Tritium counts in the plasma are charted. (C) Tritium 
counts in plasma in control mice (solid line) or in those subjected to 
lymphatic separation (dotted line) after [3H]-cholesterol–loaded macro-
phages were injected into the tail upstream (with respect to lymph flow) 
of the lymphatic separation as shown in A. (D) Compiled tritium counts 
in plasma, liver, and feces from the experimental design used in C. (E) 
Cholesterol efflux was monitored as the loss of fluorescence from gated 
CD45.1 macrophages loaded ex vivo with BODIPY-cholesterol and 
retrieved 24 hours later from the tails of WT or Apoa1 transgenic mice 
with or without lymphatic separation. All data represent the mean ± SEM 
from at least 2 experiments performed with 5 replicates per experimen-
tal group. *P < 0.05; **P < 0.01. CPM, counts per minute.
Downloaded from http://www.jci.org on January 11, 2016.   http://dx.doi.org/10.1172/JCI63685
research article
 The Journal of Clinical Investigation   http://www.jci.org 3
Genetic ablation of lymphatic vessels disrupts RCT from skin. So-
called “Chy mice” carry 1 mutant allele of the VEGF-C receptor 
VEGFR3 that controls lymphatic vessel development but does 
not affect blood vessels (11, 24). Experiments in these mice would 
avoid the need for surgical separation of lymphatics and would 
instead comprise a genetic approach to addressing the quan-
titative importance of lymphatic vessels in RCT. Chy mice are 
reported to selectively lack lymphatic capillaries in skin (25). We 
observed that the loss of lymphatic vessels was complete in the 
limbs and ears of Chy mice, but that the body trunk skin retains 
some lymphatic vasculature (26). This retention in the body trunk 
resulted in normal immune cell trafficking through lymph, with 
molecular transport that was partially reduced, but less substan-
tially so, than in the footpads or the ear (26). Chy mice, whether 
on their original mixed-strain background or backcrossed 10 
generations onto the C57BL/6 background, had profoundly 
reduced RCT when they served as recipients of [3H]-cholesterol– 
loaded macrophages injected into the rear footpad. Mean reduc-
tions in plasma at 24 hours were 77% and 74% for the 2 Chy 
strains (Figure 2A), with a net reduction in RCT of 69% when we 
compiled [3H]-cholesterol counts in the liver, plasma, and feces 
(Figure 2B). By contrast, injection of [3H]-cholesterol macro-
phages in the body trunk skin where there were residual, though 
still reduced, lymphatic vessels led to only a mean 25% inhibition 
of RCT (Figure 2C), indicating that the impaired RCT correlated 
with the extent of lymphatic vessel loss of transport. Plasma lipo-
protein profiles were similar (Figure 2D), but HDL was actually 
increased in Chy mice on the C57BL/6 background relative to 
their littermate controls (Figure 2D), making the impaired RCT 
in these mice even more striking. Thus, these data using a genetic 
model confirm the critical importance of lymphatic transport in 
RCT. The overall greater reduction in RCT in Chy mice compared 
with the surgical model may be due to substantial, but incom-
plete, blockade of lymphatic drainage in the surgical model (Fig-
ure 1A) relative to the genetic model.
Vascular leakiness does not obviate the importance of lymphatic vessels in 
RCT. We next examined whether lymphatic vessels would still retain 
an important role in RCT at sites where the blood vasculature was 
leaky, potentially increasing direct transfer of HDL into the vas-
culature. To set up a tractable model with a leaky vasculature as a 
defining feature, we took advantage of the fact that tumors have a 
leaky vasculature. Lewis Lung Carcinoma (LLC) cells were allowed 
to form tumors in the ear pinnae of Chy mice or their littermate 
controls (Figure 3A). Extravasated Evans blue dye within the ear, 
Figure 2
RCT in Chy mutant mice. (A) [3H]-Cholesterol–loaded macrophages 
were injected into the rear footpads of Chy mice or control littermates 
and tritium counts were assessed in plasma at 24 hours. Two back-
ground strains were compared; injected macrophages were made from 
the bone marrow of mice on the same background as the recipients 
into which they were injected. (B) Compiled tritium counts in plasma 
(black), liver (white), and feces (gray) from C57BL/6 Chy and WT mice 
euthanized 24 hours after [3H]-cholesterol–loaded macrophages were 
injected into the rear footpad. (C) Compiled tritium counts in plasma 
(black), liver (white), and feces (gray) from C57BL/6 Chy and WT mice 
euthanized 24 hours after [3H]-cholesterol–loaded macrophages were 
injected into the scapular area of the back skin. (D) Lipoprotein pro-
files in the plasma of Chy mice and littermate controls from the mixed 
or C57BL/6 backgrounds. Each panel represents 2 experiments per-
formed with 5 replicates per experimental group (mean ± SEM). Statis-
tics compared Chy mice with their control littermates in each case. 
*P < 0.05; **P < 0.01; ***P < 0.001.
Figure 3
Impact of vascular leakage on RCT through lymphatic vessels. (A) LLC cells were injected into the ear pinnae of Chy and control littermates (mice 
on a mixed background were used). Tumors grew for 3 weeks before [3H]-cholesterol–loaded macrophages were injected as shown. (B) Increased 
vascular permeability was documented using Evans blue dye injected i.v. with extraction of ear tissue 30 minutes later to quantify dye recovery 
using a spectrophotometer. (C) Analysis of tritium counts in the plasma 24 and 48 hours later. Tumor-bearing mice were housed by requirement 
under biohazard containment that precluded the use of individual caging needed to collect feces. Each panel represents 2 experiments performed 
with 5 replicates per experimental group. Data represent the mean ± SEM comparing indicated conditions (B) or Chy and control mice at each 
time point (C). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001.
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measured 30 minutes after i.v. injection, confirmed enhanced vas-
cular leakage in the tumor and surrounding tissue (Figure 3B). 
[3H]-Cholesterol–loaded macrophages were injected adjacent 
to the tumor, upstream with respect to lymphatic flow through 
the tumor-bearing skin, as indicated in Figure 3A. A marked 
reduction in RCT (54%) was observed in Chy mice (Figure 3C), 
indicating that lymphatic vessels remain dominant conduits for 
RCT, even in tissues characterized by a leaky vasculature.
RCT from atherosclerotic aortae is impaired by anti-VEGFR3 mAb 
that attenuates lymphatic vessel growth. To assess the potential rel-
evance of findings in skin to the mode of cholesterol transport 
in the aortic wall, lymphatic vessels were first identified in the 
adventitia and surrounding adipose tissue of the entire aorta of 
WT mice and in Apoe–/– mice with atherosclerosis (Figure 4A). 
These vessels were absorptive lymphatic capillaries, as opposed 
to lymphatic collecting vessels that transport lymph but do 
not absorb, since they stained for both LYVE-1 and podoplanin 
(11, 27, 28). The identified lymphatic capillaries wove in and out 
of the adjacent adipose tissue and were therefore difficult to keep 
completely intact when dissecting the aorta. A lymphatic capil-
lary in the adventitia of the lesser curvature proximal to the aortic 
sinus was consistently observed (Figure 4, B and C, arrow). Lym-
phatic vessels around the arteries that branch off the aortic arch 
were observed, but their locations appeared more inconsistent, as 
in Figure 4, B and C (arrowheads), which shows 2 specimens with 
lymphatic vessels around different branching arteries. Lymphatic 
vessels were richly abundant beneath plaques in the aortic sinus 
(Figure 4D), again surrounded by adipose tissue.
The surgical and genetic approaches used above are unsuit-
able for assessing whether lymphatic vessels mediate RCT from 
experimental atherosclerotic plaques. First, it is not technically 
feasible to surgically disconnect lymphatic vessels from the intact 
aorta. Second, in the genetic model of Chy mice, lymphatic vessels 
were not absent in the aortic sinus (Figure 4E) or the arterial tree 
(data not shown), but were absent in the skin. Indeed, Chy mice 
and other genetic models of lymphatic vessel loss appear to have 
relatively normal lymphatic vessels at non-skin sites (25, 29). To 
generate a tractable model for the study of RCT, we turned to a 
surgical model in which the aortic arch is transplanted into the 
abdominal cavity of a recipient mouse. When the recipient is WT 
and, therefore, has low LDL, this model supports robust disease 
regression (30–32). The appeal of the model in our case was that 
the surgery itself disrupts lymphatic connections and thus could 
be used to determine whether reestablishing lymphatic connec-
tions led to differences in RCT.
We have reported that lymphatic vessels are regenerated within 
3 days or less in the adventitia of the surgical site, which drains 
lymph to the iliac lymph nodes (32). To better control the tim-
ing of cholesterol efflux in this model, we surgically transplanted 
aortic arches from Apoe–/– mice containing atherosclerotic plaques 
into the abdominal aortae of Apoe–/– recipients, rather than in WT 
recipients that will undergo spontaneous regression. In Apoe–/– 
recipients, which do not spontaneously regress (31), we could syn-
chronously induce cholesterol efflux, as a key step in regression 
and a prerequisite for RCT, by administering an apoE expression 
vector at a given time point (1, 33). Immediately after surgery, 
one-half of the recipient mice were treated with neutralizing anti-
VEGFR3 mAb AFL4 (34, 35) to selectively inhibit reformation of 
an intact draining lymphatic vasculature, or with isotype-matched 
control mAb that would allow lymphatics to reform. Prior to 
transplantation, donor aortae were loaded with stable isotope–
labeled (deuterium-labeled) cholesterol ([2H]6-cholesterol; D6-cho-
lesterol) using D6-cholesterol–rich liposomes delivered i.v. Deliv-
ery of D6-cholesterol to mice i.v. led to its rapid accumulation 
in multiple organs, including high levels in the spleen and liver 
initially (Figure 5A). D6-cholesterol was found mostly as unester-
ified cholesterol in spleen and liver (Figure 5A), suggesting that it 
either remained packaged in liposomes or was transiently incorpo-
rated into cell membranes. However, in the aorta, where D6-cho-
Figure 4
Lymphatic vessel distribution in the mouse aorta and aortic sinus. 
(A) The descending aorta is seen through its autofluorescence in the 
green channel. Vessels staining positively for podoplanin and LYVE-1 
are seen on the adventitial side of the aorta, weaving in and out of 
adjacent adipose tissue. These vessels lack smooth muscle actin 
(SMA) coverage, though some nearby blood vessels are positive. 
LYVE-1+ SMA– lymphatic vessels are absorptive lymphatic capillaries, 
rather than lymphatic collecting vessels. (B and C) LYVE-1 staining in 
the region of the aortic arch. Arrows point to a lymphatic capillary along 
the lesser curvature; arrowheads point out lymphatic capillaries near 
arteries that branch off the arch. (D) Cross-sectional analysis of the 
aortic sinus in an Apoe–/– mouse reveals lymphatic vessels under the 
areas where plaque typically develops. (E) Both WT littermates and 
Chy mice develop lymphatic vessels in the aorta as depicted in these 
cross sections of the aortic sinus.
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lesterol levels remained stable for up to 2 weeks, D6-cholesterol 
increasingly entered the cholesterol ester pool, indicating that it 
was incorporating into foam cells (Figure 5A). In plasma, high lev-
els of D6-cholesterol were observed as early as 10 minutes after 
D6-cholesterol delivery. By 2 weeks, most of the D6-cholesterol 
had cleared from the circulation and much of what remained was 
found in the pool of esterified cholesterol (Figure 5A), which in 
this case is most likely because cholesterol was esterified by plasma 
lecithin:cholesterol acyltransferase (LCAT).
Two weeks after transplantation and treatment with anti-
VEGFR3 or control mAb, we injected Apoe–/– recipients with an 
apoE-encoding adenoviral vector (36) to induce cholesterol efflux 
from plaque macrophages while mAb treatment continued. Previ-
ous results suggest that within 2 weeks cholesterol esters would be 
reduced within plaques as they undergo mobilization from mac-
rophages (1). Therefore, 2 weeks after apoE vector treatment, we 
harvested transplanted aortae and quantified D6-cholesterol by 
mass spectrometry. The transplanted aortic segment was collected 
for this analysis, with most of the transplanted segment used for 
mass spectrometric analysis and only a margin of the transplant 
and its connection to the original aorta was retained for imaging 
(Figure 5B). Two transplants were carried out per day with 1 recip-
ient in the pair receiving control mAb and the other receiving anti-
VEGFR3 mAb. Images of the transplant interface near the original 
aorta, shown here for 2 of the transplant pairs, revealed vigorous 
lymphatic growth associated with transplantation (Figure 5C). 
Figure 5
Role of lymphatic vessels in RCT from aortae. (A) Kinetics of D6-cholesterol were analyzed in duplicate 1 or 14 days after liposomes contain-
ing D6-cholesterol were administered i.v. Solid lines correspond to the left-hand y-axis that plots ng of D6-cholesterol detected in aortae. Data 
depicted by dotted lines correspond to the right-hand y-axis that plots the esterified/total D6-cholesterol ratio. (B) Schematic diagram of the aortic 
transplant positioned in the abdominal aorta. Green box depicts the portion of tissue collected for mass spectrometric (MS) analysis; orange box 
shows the portion of tissue collected for imaging lymphatic regrowth. (C) Images of 2 independent pairings of mice transplanted on the same 
day, 1 treated with control mAb and the other with anti-VEGFR3 mAb; stained for LYVE-1 (white vessels). Stars depict location of the lumen of 
the transplanted aortic arch where it connects with the original aorta. Arrowheads point to surgical sutures that demarcate the boundary between 
the transplant (Tx) and the original aorta (OA). Upper images show a pairing from 2 different orientations and lower images show a side view of 
a different surgical pair. Scale bars: 250 μm. (D) Ester/total D6-cholesterol achieved at baseline prior to transplantation and ratios recovered in 5 
pairs of transplants 4 weeks after surgery, treated with apoE vector at 2 weeks and with control or anti-VEGFR3 throughout (E and F). Total (E) 
and esterified (F) D6-cholesterol recovered in pairs treated with control or anti-VEGFR3 mAb. D and E depict data as the mean ± SD (n = 5–9 
for each bar). *P ≤ 0.05.
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The new vessels were differently oriented than the preexisting 
vessels (compare Figure 4A with Figure 5C). This difference likely 
reflects altered blood flow associated with the transplant, as blood 
flow would determine patterns of interstitial fluid flow through 
the aortic wall, in turn influencing lymphangiogenesis pattern-
ing (37). Lymphatic regrowth after transplantation was inhib-
ited, albeit not completely, with anti-VEGFR3 mAb (Figure 5C). 
Anti-VEGFR3 mAb treatment did not lead to impaired lymphatic 
transport when assessed in skin (Supplemental Figure 3), suggest-
ing that its main action was on the redevelopment of lymphatics 
rather than on the transport function of existing vessels. However, 
it was not possible to inject lymph flow tracers into the aortic wall 
to quantify lymph transport locally.
As for the fate of D6-cholesterol, a very high proportion of 
D6-cholesterol was located in the ester pool prior to transplanta-
tion (baseline) (Figure 5D), indicating that it was largely confined 
to foam cells or intact lipoproteins in the aortic wall, rather than 
less relevant compartments such as the medial smooth muscle 
wall where it would be found as free D6-cholesterol. Even with 
partial inhibition of lymphatic regrowth, anti-VEGFR3 mAb 
treatment led to a greater retention of D6-cholesterol in the 
transplanted aortae compared with those treated with control 
mAb (Figure 5E), especially within the ester pool of D6-choles-
terol (Figure 5, D and F). Since Vegfr3 mRNA was not expressed in 
plaque macrophages (Supplemental Figure 4 and Supplemental 
Methods), these data indicate that VEGFR3-mediated reforma-
tion of lymphatic connections in the aorta mediates RCT.
Discussion
With only a handful of clinical or experimental observations, a 
few physicians as far back as the early 1980s have discussed the 
logic of considering that a connection between atherosclerosis and 
decreased lymph transport of cholesterol deserves attention (38–40). 
However, to date, the quantitative importance of lymphatic ves-
sels in RCT has not been examined, aside from a compelling study 
that estimated that the net flux of HDL-C through human lymph 
is substantial (14). With respect to atherosclerosis, the process of 
macrophage RCT is most relevant, and many details have emerged 
as to how cholesterol is mobilized from macrophages (6). Removal 
of cholesterol from tissues where macrophages reside for subse-
quent return to the plasma and then the liver en route to fecal 
secretion seems to logically involve lymphatic vessels. Indeed, 
lymphatic vessels have widespread importance in macromolecular 
transport from peripheral tissues in general.
Here, we provide experimental evidence that lymphatic vessels 
are critical during macrophage RCT to bring lipidated apoA-I or 
HDL-C to the plasma. We started our analysis in skin and chose 
to employ a model where we could surgically disrupt lymphatic 
transport from the mouse tail. This procedure necessitated the 
injection of cholesterol-loaded macrophages into the mouse tail, 
a site distinct from the peritoneal cavity where this assay for mac-
rophage RCT was originally developed (6). It became clear that 
macrophage RCT from the tail site was far less efficient than RCT 
from the peritoneum and that other body sites, like the footpad, 
were intermediate. This finding illustrates that different tissue 
environments vary in their ability to support RCT and raises 
important considerations that have yet to be explored, including 
whether RCT from atherosclerotic plaque is quantitatively more 
similar in the mouse tail or in the peritoneum; whether the rather 
low RCT in the tail is due to tight macrophage packing in the 
tail (as occurs in atherosclerotic plaque) that might limit apoA-1 
access to the cells compared with dispersion of macrophages in 
the peritoneum; or whether apoA1 levels in interstitial fluid vary 
between organs or body sites.
We were able to counter poor macrophage RCT from the tail 
by using Apoa1 transgenic mice and went on to uncover a quan-
titatively important role for lymphatic vessels in RCT that could 
not be attributed to altered cholesterol efflux from macrophages. 
When tail lymphatic vessels were surgically separated, we observed 
a reduction in RCT of 50%. This reduction in RCT compared sim-
ilarly to the magnitude of inhibition observed from compound 
inhibition of ABCA1 and ABCG1 (19), key transporters for the 
donation of free cholesterol to apoA-I during macrophage cho-
lesterol efflux. An even more dramatic inhibition of RCT was 
observed in the Chy mouse strain, which bears 1 copy of mutant 
VEGFR3 with attenuated signaling. This loss of only 1 functional 
VEGFR3 receptor is sufficient to prevent lymphatic vessels from 
developing in many skin sites (29), most notably the extremities 
(26). However, at other body sites, lymphatic vessels are not atten-
uated unless both copies of VEGFR3 are lost, a condition that is 
incompatible with survival during embryogenesis (41). Indeed, 
even in some skin sites, Chy mice have residual lymphatic vessels 
(26), allowing us to show that the magnitude of inhibited RCT 
correlated with the extent to which lymphatic vessels were absent 
from the skin surrounding the site where cholesterol-loaded mac-
rophages were injected.
We next considered the role of lymphatic vessels in RCT in the 
aortic wall. Technically, this issue is challenging and none of the 
models used in skin were valuable in the atherosclerosis-affected 
aorta. We reasoned that a previous surgical model used to study 
plaque regression had features necessary to address the main 
technical obstacles (confining the D6-cholesterol tracer to the 
aortic wall and disrupting the lymphatics, a natural consequence 
of the surgery). The lymphatic regrowth that occurred in the con-
trols was impressive, and this robust response may contribute 
to why the surgical model allows for what appears to be more 
aggressive regression than other models (1, 42). Unfortunately, it 
is not technically possible to quantify lymphatic transport from 
the aorta to determine whether anti-VEGFR3 mAb also affected 
lymph transport in the aortic wall, but transport was not affected 
systemically. Indeed, it has been established in a variety of scenar-
ios that anti-VEGFR3 blocks the growth of new lymphatic vessels 
but does not affect existing lymphatic vessels (35, 43–46). Thus, 
the partial inhibition of lymphatic regrowth that we observed in 
the aortae of anti-VEGFR3 likely accounts for its effect on retain-
ing cholesterol in the wall of the transplanted aortic segments 
relative to the controls. As we took measures to ensure that the 
D6-cholesterol was largely in the esterified pool at the time of 
transplantation, the cholesterol we traced originated either in 
macrophages or in intact lipoproteins, which are the two dom-
inant pools of cholesterol ester directly relevant to our study. 
Cholesterol-laden macrophages and trapped lipoproteins are far 
more abundant in intimal plaques than in adventitia. Indeed, 
past studies have measured cholesterol esters in the aorta as a 
surrogate for atherosclerotic plaque (47, 48). Thus, our findings 
support the concept that clearance of cholesterol by RCT from 
the arterial intima relies on lymphatic vessels.
Except in the most advanced plaques, where lymphatic capillar-
ies can invade the intima along with the vasa vasorum (49), this 
lymphatic vessel–driven mode of RCT would likely require that 
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HDL-C cross the media to gain access to the adventitia. The lit-
erature suggests that such movement may preferentially occur 
through pressure-driven convection (50, 51) and that hydrau-
lic conductivity across the media is increased in the context of 
hypercholesterolemia (52). Future studies are needed to continue 
to investigate the role of lymphatic vessels in atherosclerosis and 
RCT. However, the present findings indicate that the notion of 
lymphatic vessels as a conduit for cholesterol transport from ath-
erosclerotic plaques is a viable concept and that lymphatic vessel 
biology in the area of atherosclerosis needs increased attention.
In past studies, we found that lymphatic transport is decreased 
by hypercholesterolemia in Apoe–/– mice (27), and studies in 
humans revealed that the rate of lymphatic transport was inversely 
proportional to cholesterol traversing the lymph (12). This 
reduced transport that occurs in the presence of high cholesterol 
may promote cholesterol accumulation in the artery wall, as well 
as in tissues like skin that are affected in hypercholesterolemia. 
Even during conditions that support disease regression, choles-
terol removal from plaques is not as rapid as other steps in disease 
reversal. In particular, we were surprised to find that monocyte 
recruitment is greatly reduced at a time when cholesterol clearance 
from plaques is just getting underway (1). While the observation 
may suggest that removal of bulk cholesterol is only part of what 
is needed to reverse the progression of atherosclerosis, we view the 
sluggish removal of cholesterol from plaques as a risk for allow-
ing retained cholesterol to readily return to a state that supports 
plaque progression. We argue that a more desirable disease-protec-
tive state is one in which cholesterol is mobilized from the aortic 
wall in concert with treatments that support lesion stabilization 
or regression. Thus, our next step is to identify strategies to restore 
the impaired lymphatic transport that results from hypercholes-
terolemia and to determine whether such strategies can serve to 
enhance the mobilization of cholesterol out of plaques when dis-
ease-reversing regimens are concurrently applied.
Methods
Mice. WT and Apoa1 transgenic mice (both C57BL/6) were obtained from 
the National Cancer Institute (Frederick, Maryland, USA) and The Jack-
son Laboratories (Bar Harbor, Maine, USA), respectively. Chy embryos 
were purchased from the Medical Research Council (MRC, Harwell, United 
Kingdom) on a mixed C3H/HeH and 101/H background. A colony was 
established and backcrossed to the C57BL/6 background. Since 1 mutant 
allele is sufficient to confer loss of skin lymphatics (25), all control mice 
were littermates bearing no copies of the mutations. Macrophages lacking 
Abca1 and Abcg1 were obtained from mice housed at Columbia University. 
Experiments were approved by the animal oversight committees at Mount 
Sinai School of Medicine or Washington University.
Separation of lymphatic vessels in the mouse tail. We utilized a surgical tech-
nique to separate the dermal lymphatics while leaving the primary blood 
circulation intact along the tail core (20). Briefly, tails were incised circum-
ferentially at 2 locations spaced 2 mm apart, with the proximal incision 
1 cm from the base of the tail through the skin. Skin between the 2 inci-
sions was removed sufficiently to separate the lymphatic vasculature. 
Extreme caution was taken to avoid damaging the underlying vasculature. 
As a sham control, the tip of the tail was clipped to create an acute-phase 
reaction without lymphedema. Plasma lipoproteins were analyzed as 
described (1). In some mice, Evans blue dye was injected immediately after 
surgery to verify the block in lymph drainage. For RCT studies, macro-
phages were injected immediately after the surgical separation of lymphat-
ics or sham, avoiding significant lymphedema during the 48-hour assay.
Cholesterol-loaded macrophages and efflux using BODIPY-cholesterol. Total 
bone marrow was obtained from mice by flushing femurs and tibiae of 
mice with RPMI-1640. L929-conditioned medium was used to generate 
bone marrow–derived macrophages (BMDMs) over a 6-day culture period. 
To induce foam cell formation and label the intracellular cholesterol 
pool, BMDMs were loaded on the sixth day of culture for 24 or 48 hours 
in the presence of 100 μg/ml acetylated LDL (acLDL) that was previ-
ously incubated for 30 minutes at 37°C with 5 μM BODIPY-cholesterol 
(23) (dissolved in ethanol) or 2.5 μCi/ml [3H]-cholesterol (PerkinElmer), 
respectively. After 24 or 48 hours, respectively, cells were removed from 
the culture dish using nonenzymatic cell dissociation medium (Cellgro, 
Corning), washed twice with RPMI-1640, and equilibrated in 0.2% BSA 
for 4 hours before injection. When cholesterol efflux was assessed in vitro, 
BODIPY-cholesterol–loaded macrophages were cultured for 20 hours in 
5% mouse serum. Cholesterol efflux was assessed directly on a single-cell 
level by fluorescence microscopy or flow cytometry. After implantation in 
vivo, transferred macrophages were retrieved from the skin by digesting the 
skin with Liberase TM (Roche Applied Science) and staining for CD45.1 
with exclusion of dead cells using propidium iodide.
In vivo RCT assay. To assess in vivo RCT, a total of 2.0 × 106 [3H]-choles-
terol–labeled BMDMs containing 7 × 105 cpm were injected per mouse. 
Cells were injected either i.p. (500 μl) or intracutaneously (20 μl) into the 
footpad, back skin, or tail skin as indicated in Figures 1–3. Then mice were 
housed individually in clean cages to allow for the collection of fresh feces 
24 and 48 hours later. As in previous work (18), blood was collected at 24 
and 48 hours, and plasma volume was measured and used for liquid scin-
tillation counting. Feces were collected at 24 and 48 hours, as indicated 
in Figures 1–3. Feces and livers were also weighed and subjected to liquid 
scintillation counting.
Lipoprotein analysis. Total cholesterol levels were determined using a Wako 
kit (catalog no. 439-17501) according to the manufacturer’s protocol. 
Lipoprotein cholesterol distributions were determined using plasma sam-
ples diluted 1:1 in cold PBS centrifuged at 10,000 g for 2 minutes at 4°C. 
Approximately 15 mg of cholesterol was injected into an HPLC system with 
online mixing of enzymatic reagent (Cholesterol Liquid Reagent Set, Pointe 
Scientific) with effluent from the column. The HPLC system consisted of 
a Superose 6 10/300 GL column (GE Healthcare); a LaChrom Elite HPLC 
system (Hitachi High Technologies) consisting of an L-2200 Autosampler 
with Peltier cooling, an L-2420 UV-Vis Detector, and two L-2100 SMASH 
pumps — 1 for delivering 0.9% saline with 0.01% EDTA and 0.01% sodium 
azide at 0.4 ml/min to the column, and the other for delivering cholesterol 
reagent (or water) at 0.125 ml/min; a 5 m (length) × 0.5 mm (internal diam-
eter) knitted reaction coil (KRC 5-50; Aura Industries) in a water jacket 
(CJB-10; Aura Industries) at 37°C; an Isotemp circulating water bath (Fisher 
Scientific); a PEEK Tee (Upchurch part no. P-712) at the junction of column 
effluent and total cholesterol reagent; and a personal computer running 
ChromPerfect Spirit Chromatography Data System software, version 5.5 
(Justice Laboratory Software) for data acquisition and analysis.
Tumors and vascular leakage assay. LLC cells (1.0 × 106 or 5.0 × 105) were 
injected into the skin of the ear and allowed to grow for 3 weeks. A total of 
5.0 × 106 [3H]-cholesterol–labeled foam cells containing 1.2 × 106 cpm were 
injected intradermally in a single injection of 10 μl in the tip of the ear near 
the tumor. To assess vascular leakage, mice were anesthetized and 200 μl of 2% 
Evans blue dye (Sigma-Aldrich) was injected into the orbital vein. Thirty min-
utes later, the mice were euthanized and their ears were removed, and the blue 
dye was extracted from skin using N,N-dimethylformamide (Sigma-Aldrich) 
for 24 hours at 56°C and measured with a spectrophotometer (630 nm).
Aortic transplant procedure. Liposomes were prepared using cholester-
ol-26,26,26,27,27,27-d6 (D6-cholesterol) obtained from Sigma-Aldrich and 
1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) obtained from 
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Avanti Polar Lipids. Ten milligrams (0.0255 mmol) of D6-cholesterol and 
200 mg (0.263 mmol) of POPC were dissolved in chloroform, mixed, dried 
onto the bottom of 13 × 100 mm glass tubes, and dried under vacuum 
overnight. The next day, 6 ml of sterile saline was added to the tubes, which 
were incubated for 1 hour at 40°C. The tubes were vortexed on a mechan-
ical agitator for approximately 2–3 hours. Liposomes were stored at room 
temperature until ready for injection.
Nineteen to 21-week-old Apoe–/– donor mice, placed on a Western diet at 
6 weeks of age (Harlan Teklad 88137), received a 250 μl bolus injection of a 
suspension of liposomes containing D6-cholesterol. Following treatment, 
these donors were housed for 2 weeks to allow esterification of D6-choles-
terol in plaques. Then heterotopic aortic transplants of the aortic arch (53) 
were carried out in similarly aged and Western diet–fed Apoe–/– recipients. 
Two surgeries were conducted each day. Immediately after surgery, the 2 
mice were given 1.2 mg of AFL4 anti-VEGFR3 mAb (LEAF Purified; BioLeg-
end) or isotype-matched control mAb (rat IgG2a, LEAF Purified; Biolegend) 
i.p., respectively, and 0.6 mg every other day for a total of 4 weeks. Two weeks 
after surgery, pairs were treated with apoE-encoding adenoviral vector (Sig-
naGen) (1, 33). Pairs were euthanized 2 weeks after vector treatment, and 
the transplant tissue was harvested for mass spectrometry or imaging as 
specified. Liver and plasma samples were also collected, but D6-cholesterol 
levels were too low for detection at the time of collection in these tissues.
Cholesterol analysis by GC-MS. Sample preparation was conducted by 
a modification of a previously reported procedure (54). Briefly, lipids 
were extracted according to Bligh and Dyer (55) after adding 4 μg of 
[3,4-13C2]-labeled cholesterol as the internal standard. Extracts were evap-
orated under a stream of argon, dissolved in 1 ml of chloroform/methanol 
(1:1) and stored at –80°C until analyzed. To measure free cholesterol, a 
50-μl aliquot of each extract was evaporated under argon, and the residue 
was dissolved in toluene and analyzed using a Finnigan TSQ Quantum 
XLS mass spectrometer interfaced to a Trace gas chromatograph. To mea-
sure the total cholesterol, another 50-μl aliquot was saponified at room 
temperature for 2 hours with methanolic KOH, cooled, and then extracted 
with hexane. The hexane was evaporated under argon, and the residue was 
dissolved in toluene and analyzed.
Samples of 1 μl each were injected onto a 250 μm × 10 m DB-1 capillary 
column (J&W Scientific, Agilent Technologies). Helium was the carrier 
gas at a constant flow rate of 1.0 ml per minute. The SSL injector tem-
perature was 280°C, the interface 260°C, and the source 260°C. An oven 
temperature program was used: 150°C for 1 minute, increased at 25°C per 
minute to 215°C, followed by a 50-minute hold, then increased at 35°C 
per minute to 260°C, followed by a 3.8-minute hold. The thermo triple 
quadrupole (TSQ) was operated with the electron impact source in the pos-
itive-ion mode with a potential of 42 eV. Data were acquired in the selective 
ion-reaction mode monitoring the following decompositions for choles-
terol: 386.3 m/z > 301.3 m/z, for [3,4-13C2]-cholesterol; 388 m/z > 301.3 m/z 
and 392.3 m/z > 307.3 m/z for [26,26,26,27,27,27-d6]-cholesterol. The col-
lision cell energy was 10 V and the gas pressure was 1.0 mTorr. Corrections 
were made for the 13C natural abundance. Ester cholesterol is reported as 
the difference between total cholesterol and free cholesterol.
Statistics. Data are expressed as the mean ± SEM or SD, as indicated. 
Statistical differences were assessed using a 2-tailed Student’s t test (when 
comparing 2 datasets) or ANOVA (3 or more datasets) with Prism software, 
version 4.2 (GraphPad).
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